Prostate cancer

Cancer Treatment: A Look at How It Has Evolved in 70 Years

by

In 1947, when Dana-Farber Cancer Institute founder Sidney Farber, MD, set out to find a drug treatment for childhood leukemia, cancer treatment took two forms – surgery to cut out cancerous masses, and radiation therapy to burn them out. Cancers that couldn’t be removed or irradiated – either because of their position in the body, because … Read more

Online Tool Offers Guidance for Men with Non-Metastatic Prostate Cancer

by

Men diagnosed with non-metastatic prostate cancer now have access to a new tool on the TrueNTH USA website to help them prepare for their first meeting with a cancer physician. The tool, called Personal Patient Profile-Prostate (P3P), was created by Dana-Farber researchers and is now available to all men with non-metastatic prostate cancer though TrueNTH … Read more

What Is ‘Watchful Waiting’ and When Is it Right for Prostate Cancer?

by

According to the American Cancer Society, more than 180,000 men will be diagnosed with prostate cancer this year, with African American men 60 percent more likely to develop the disease than other ethnic groups. Fortunately, the vast majority of prostate cancer diagnoses will be a slow-growing, highly treatable form of the disease. For many men diagnosed … Read more

Cancer Conversations Podcast—Episode #16: The Latest in Prostate Cancer Treatment and Research

by

Prostate cancer affects 230,000 men each year. Although diagnoses are increasing worldwide, most people die with prostate cancer and not of prostate cancer, according to Mark Pomerantz, MD, a medical oncologist in Dana-Farber’s Lank Center for Genitourinary Oncology. In this Cancer Conversations podcast episode, Pomerantz discusses genetics, risk factors, and the controversy surrounding the PSA … Read more

The Latest in Prostate Cancer Research and Treatment

by

Prostate cancer is the most common cancer affecting men in the United States, after skin cancer. Yet, “most men die with prostate cancer, not of prostate cancer,” says Mark Pomerantz, MD, a medical oncologist in Dana-Farber’s Lank Center for Genitourinary Oncology, who recently shared the latest in prostate cancer research and treatment during a live … Read more

Does Cycling Increase Risk for Testicular or Prostate Cancer?

by

Since professional cyclist Lance Armstrong was diagnosed with testicular cancer in 1996, many men have wondered about the connection between cycling and testicular cancer, as well as prostate cancer. While a number of studies have looked into a link between the sport and cancer, the findings to date are inconclusive, says Mark Pomerantz, MD. “This … Read more

Understanding PSA Scores

by

Just as there is no one-size-fits-all number for high blood pressure, a variety of factors can influence whether a man’s PSA score is considered above normal. PSA, or prostate-specific antigen, is a protein that’s often associated with prostate cancer. A PSA test measures the level of the protein in a man’s blood. A score of … Read more

Progress and Promise in Prostate Cancer Research

by

In prostate cancer – the most common cancer in men aside from skin cancer – scientists are working to answer some of the most basic questions about the disease while developing an array of new treatments.

Using the prostate-specific antigen (PSA) blood test, doctors are often able to detect prostate cancer at an early stage. But it remains difficult to determine which prostate cancers are likely to spread – and therefore require aggressive treatment – and which are either idle or slow-growing, and can be dealt with by “observation or active surveillance.” This uncertainty could result in unnecessary treatment for some patients.

Read more

New Findings May Change Treatment of Advanced Prostate Cancer

by

For about 70 years, the standard treatment for patients with advanced prostate cancer was drugs that blocked male hormones feeding the tumor. If that stopped working and the disease progressed, oncologists turned to chemotherapy to kill the cancer cells.

This timetable is about to change. Results of a clinical trial led by a Dana-Farber researcher revealed that such patients lived longer if started on both a hormone blocker and a chemotherapy drug at the same time. The government-sponsored trial found that 69 percent of men receiving both treatments were alive at three years, compared with 52.5 percent of men who initially got just the hormone blocker. The advantage was so striking – especially for patients with greater degrees of cancer spread – that the National Cancer Institute publicized the findings ahead of schedule to alert doctors and patients.

“The results of this study are practice-changing for some patients,” says Christopher Sweeney, MBBS, clinical director of Dana-Farber’s Lank Center for Genitourinary Cancer, who headed the trial. We asked him to explain:

Read more

Can a Vasectomy Increase a Man’s Risk of Prostate or Testicular Cancer?

by

By Mark Pomerantz, MD

There has been some uncertainty surrounding this question, but recent studies have demonstrated that having a vasectomy has no effect on the risk of prostate or testicular cancer.

Older data – from studies tracking disease rates across broad population groups – suggested a modest connection, while other studies found no such link.

Read more